RS-2024-00462810

# Development of mutant PI3Kalpha chaperone-mediated degrader candidate

**MagicBullet Therapeutics**

매직불릿 테라퓨틱스
MAGICBULLET THERAPEUTICS

**ONCOLOGY** | **Candidate**

| | |
|---|---|
| Product Type | Targeted protein degradation (TPD) |
| Indication | Breast cancer |
| Target | PI3Kα |
| MoA(Mechanism of Action) | Based on several advantages of PROTAC approach, hetero-bifunctional PI3Kα-chaperone degrader simultaneously binds mutant PI3Kα and HSP90 chaperone to form a ternary complex, which subsequently leads to PI3Kα protein degradation by hijacking ubiquitin-proteasome system (UPS) and inhibiting its downstream activity. |
| Competitiveness | • A first-in-class, potent, orally bioavailable, hetero-bifunctional PI3Kα -chaperone degrader<br>• Broad mtPI3Kα degradation effect of PI3Kα-chaperone degrader compared to alpelisib and inavolisib on breast cancer cells<br>• Opportunity to expand therapeutic indications |
| Development Stage | Candidate |
| Route of Administration | Oral administration |

kddf_bd@kddf.org
KDDF Business Development Team

KDDF
Korea Drug Development Fund